The observation that pioglitazone increased Abcg1 expression in macrophages, reduced cholesterol accumulation, and reduced disease severity in PAP mice supports the feasibility of its use as pharmacotherapy of PAP in humans. The gene discussed is ABCG1; the disease is pulmonary alveolar proteinosis.